Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

A Molecular Deep Dive Into BRAF-Mutant Colorectal Cancer

Program Information

Program Information

ReachMD Healthcare Image

    Up to 15% of patients with metastatic colorectal cancer harbor a BRAF mutation, which is why we’re examining its pathways and mechanisms.

    • Overview

      BRAF-mutated colorectal cancer tumors represent a distinct biological entity, and considerable research has been focused on learning more about this aggressive subtype with generally poor prognosis. Oncologist Dr Andrea Cercek joins Dr Charles Turck to discuss the pathways and mechanisms of BRAF-mutant colorectal cancer, including its various distinctions.

      © 2021 Pfizer Inc. All rights reserved. PP-BCE-USA-0310 July 2021

    Schedule26 Jan 2022
    Webpack App